Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: A retrospective, comparative study at a single tertiary care institute

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Sun, Li Bo ^a   Zhao, Guo Jie ^a   Ding, Da Yong ^a   Song, Bin ^a   Hou, Rui Zhi ^a   Li, Yong Chao ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

locally advanced gastric cancer; pathological differentiation; preoperative chemotherapy; surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETTER DIFFERENTIATED LOCALLY ADVANCED GASTRIC CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER INJURY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PARTIAL GASTRECTOMY; PATHOLOGY; POORLY DIFFERENTIATED LOCALLY ADVANCED GASTRIC CANCER; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; TERTIARY HEALTH CARE; TOTAL STOMACH RESECTION; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL TRIAL; FOLLOW UP; GASTRECTOMY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PROGNOSIS; STOMACH NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TERTIARY HEALTHCARE;

EID: 84908101187     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-280     Document Type: Article

References (27)

1. Parkin DM, Whelan SL, Ferlay WJ, Teppo L, Thomas DB. Cancer Incidence in Five Continents Vol VIII 2002, Lyon, France: IARC Press, IARC Scientific Publication No. 155.
2. Zou XN, Duan JJ, Huangfu XM, Chen WQ, Zhao P. Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China, 2004-2005. Zhonghua Yu Fang Yi Xue Za Zhi 2010, 44(5):390-397.
3. Lee JH, Yom CK, Han HS. Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc 2009, 23(8):1759-1763. 10.1007/s00464-008-0198-0, 19057958.
4. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006, 24(24):3953-3598. 10.1200/JCO.2006.06.4840, 16921048.
5. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010, 16(44):5621-56218. 10.3748/wjg.v16.i44.5621, 2992682, 21105197.
6. He LF, Yang KH, Tian JH, Bai ZG. Meta analysis of clinical effectiveness of neoadjuvant chemotherapy for gastric cancer. Ai Zheng 2008, 27(4):407-412.
7. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29(13):1715-1721. 10.1200/JCO.2010.33.0597, 21444866.
8. Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer 2011, 104(12):1840-1847. 10.1038/bjc.2011.175, 3111205, 21610705.
9. Díaz-González JA, Rodríguez J, Hernández-Lizoain JL, Ciérvide R, Gaztañaga M, San Miguel I, Arbea L, Aristu JJ, Chopitea A, Martínez-Regueira F, Valentí V, García-Foncillas J, Martínez-Monge R, Sola JJ. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys 2011, 80(3):698-704. 10.1016/j.ijrobp.2010.02.054, 20656414.
10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, . MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20. 10.1056/NEJMoa055531, 16822992, MAGIC Trial Participants.
11. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856. 10.1200/JCO.2008.17.0506, 19139439.
12. Ge L, Wang HJ, Yin D, Lei C, Zhu JF, Cai XH, Zhang GQ. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. World J Gastroenterol 2012, 18(48):7384-7393. 10.3748/wjg.v18.i48.7384, 3544046, 23326149.
13. Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, Uronis HE, Czito BG. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013, 8(1):6. 10.1186/1748-717X-8-6, 3552754, 23286735.
14. Zhang C, Li G, Fan C, Xu J, Cao J, Liu S, Li N. Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol 2012, 10(8):162. 3499231, 22891660.
15. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours 2002, Geneva, Switzerland: Union for International Cancer Control, 6.
16. Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006, 94(7):959-963. 10.1038/sj.bjc.6603046, 2361232, 16552439.
17. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005, 23(3):494-501.
18. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005, 92(2):246-251. 2361863, 15655540.
19. Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am 2013, 42(2):337-357. 10.1016/j.gtc.2013.01.010, 23639644.
20. Shin D, Park SS. Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer. World J Gastrointest Oncol 2013, 5(1):4-11. 10.4251/wjgo.v5.i1.4, 3671068, 23738049.
21. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000, 87(3):236-242.
22. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004, 240(5):808-816. 10.1097/01.sla.0000143245.28656.15, 1356486, 15492562.
23. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997, 4(3):203-208. 10.1007/BF02306611, 9142380.
24. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989, 7(9):1318-1326.
25. Wilke H, Stahl M, Fink U, Meyer HJ, Siewert JR. Preoperative chemotherapy for unresectable gastric cancer. World J Surg 1995, 19(2):210-215. 10.1007/BF00308628, 7754625.
26. Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D'Angelo A, Salvagni S, Martignoni G, Beretta GD, Graziano F, Berardi R, Franciosi V, . Italian Group for the Study of Digestive Tract Cancer (GISCAD) High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 2004, 90(8):1521-1525. 10.1038/sj.bjc.6601752, 2409717, 15083179, Italian Group for the Study of Digestive Tract Cancer (GISCAD).
27. Park Y, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008, 61(4):623-629. 10.1007/s00280-007-0515-7, 17522863.